MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Working through myasthenia gravis, one story at a timeby Sarah Bendiff on July 10, 2025 at 2:00 pm
It’s been 10 months since I started writing this column, and I can honestly say that it’s changed my life. My mindset, my emotional health, and even my relationship with The post Working through myasthenia gravis, one story at a time appeared first on Myasthenia Gravis News.
- Azathioprine eases MG symptoms, but does not extend survival: Studyby Margarida Maia, PhD on July 10, 2025 at 12:00 pm
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age alone increased the risk of death, using azathioprine for many years The post Azathioprine eases MG symptoms, but does not extend survival: Study appeared first on Myasthenia Gravis News.
- How studying history can help us navigate life with chronic illnessby Mark Harrington on July 9, 2025 at 2:00 pm
I grew up in Malden, Massachusetts, surrounded by history. According to the City of Malden’s website, “In 1640, the Puritans settled in Malden on land purchased in 1629 from the The post How studying history can help us navigate life with chronic illness appeared first on Myasthenia Gravis News.
- Povetacicept reduces disease activity in MG mouse modelby Margarida Maia, PhD on July 8, 2025 at 12:00 pm
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels The post Povetacicept reduces disease activity in MG mouse model appeared first on Myasthenia Gravis News.
- The tug-of-war between my independence and his caregivingby Shawna Barnes on July 7, 2025 at 2:00 pm
After every major flare of myasthenia gravis (MG), there comes a stretch of time that feels like limbo. I call it the “gray zone” of healing. It’s that place between The post The tug-of-war between my independence and his caregiving appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.